The Latest Animal Vaccines Industry Statistics Explained
The global animal vaccines market size was valued at USD 9.24 billion in 2021.
This statistic indicates that the global animal vaccines market generated revenues of USD 9.24 billion in 2021. This market size represents the total value of sales for vaccines that are specifically designed for animals across various sectors such as livestock, companion animals, and wildlife. The figure reflects the demand for preventive healthcare measures in animals to protect them from diseases, thereby driving the growth of the animal vaccines industry. Factors contributing to this market size may include increasing awareness about animal health, rising incidences of zoonotic diseases, advancements in vaccine technology, and government initiatives promoting animal welfare. The value of USD 9.24 billion underscores the significance of the animal vaccines market in safeguarding the well-being of animals and supporting the overall ecosystem of animal health.
It is estimated that the market will grow at a CAGR of 7.8% from 2022 to 2028.
This statistic indicates that the market is projected to experience a Compound Annual Growth Rate (CAGR) of 7.8% from the year 2022 to 2028. The CAGR reflects the annual growth rate of the market over a specified period, smoothing out fluctuations that may occur year to year. A CAGR of 7.8% suggests that the market is expected to steadily expand at a consistent rate over the six-year period, leading to substantial overall growth by the end of 2028. This projection can be valuable for businesses and investors in understanding the potential trajectory of the market and making strategic decisions based on anticipated growth rates.
The canine vaccines segment accounted for the largest market share of 52.4% in 2021.
The statistic indicates that among all types of vaccines in the market in 2021, canine vaccines held the largest market share at 52.4%. This suggests that a substantial portion of the market demand for vaccines was attributed to vaccines intended for dogs. This could be due to factors such as the high prevalence of canine diseases, increasing pet ownership rates, and the emphasis on animal health and well-being. The prominence of the canine vaccines segment highlights the importance of preventive healthcare measures for pets and the significant role that these vaccines play in protecting dogs from various infectious diseases.
North America is leading the market, accounting for 36.7% of global revenues in 2021.
This statistic indicates that North America has a dominant position in the market, with the region accounting for 36.7% of total global revenues in 2021. This suggests that North America has a significant share of the market compared to other regions around the world. The high percentage of global revenues attributed to North America underscores the region’s economic strength, market influence, and potentially advanced infrastructure and consumer base. This information is valuable for market analysis and strategic decision-making, as it highlights the importance of North America as a key market for businesses looking to expand or establish a presence in the industry.
The livestock vaccines sector was worth approximately $5.8 billion in 2021.
The statistic “The livestock vaccines sector was worth approximately $5.8 billion in 2021” indicates the total market value attributed to the production and sale of vaccines specifically for livestock animals during the year 2021. This valuation reflects the economic significance and demand for vaccines within the livestock industry, highlighting the investment and resources directed towards maintaining animal health and productivity. The figure of $5.8 billion also suggests a substantial market size and potential growth opportunities within the livestock vaccines sector, emphasizing the importance of disease prevention and biosecurity measures in animal agriculture.
The DNA vaccines segment is expected to grow at the fastest CAGR of 14.2% from 2022 to 2028.
The statistic refers to the Compound Annual Growth Rate (CAGR) projection for the DNA vaccines segment, indicating that this specific market is anticipated to experience significant growth over a 6-year period from 2022 to 2028. A CAGR of 14.2% suggests a robust and steady increase in market size and demand for DNA vaccines during this period. This growth rate outpaces that of other segments within the industry, highlighting the potential for DNA vaccines to become a major player in the healthcare and biotechnology sectors. Factors such as advancements in technology, increasing awareness of the benefits of DNA vaccines, and ongoing research and development efforts are likely contributing to this optimistic growth forecast.
By 2026, the market for Animal Viral Vaccines is projected to reach $4.4 billion.
The statistic states that by the year 2026, the market for Animal Viral Vaccines is expected to grow and reach a total value of $4.4 billion. This projection suggests a substantial increase in the demand for and usage of animal viral vaccines over the next several years. The significant growth in this market can be attributed to various factors such as increasing awareness about animal health, rising investments in veterinary care, and the need to prevent and control viral diseases among animals. This statistic indicates a promising outlook for the animal health industry and the importance of vaccination in safeguarding animal populations against viral infections.
Poultry vaccines are projected to witness a CAGR of 8.1% between 2022 and 2028.
This statistic indicates that the market for poultry vaccines is expected to experience a Compound Annual Growth Rate (CAGR) of 8.1% between the years 2022 and 2028. A CAGR of 8.1% means that, on average, the market value of poultry vaccines is anticipated to increase by 8.1% every year during this time period. This projection suggests a positive outlook for the poultry vaccine industry, signaling potential growth and increasing demand for these products over the specified timeframe. Various factors such as advancements in veterinary medicine, rising awareness of animal health, and increasing adoption of preventative measures in poultry farming could contribute to this projected growth rate.
The Asia Pacific animal vaccines market is predicted to grow at the highest CAGR of 8.5% through 2028.
The statement indicates that the Asia Pacific animal vaccines market is expected to experience a Compound Annual Growth Rate (CAGR) of 8.5% over the period ending in 2028. This suggests a robust and sustained growth trajectory in the region’s animal vaccines market, with a higher rate compared to other regions. Factors such as increasing awareness about animal health, rising pet ownership, and the growing demand for livestock products are likely driving this growth. The forecasted CAGR highlights the potential for significant expansion and opportunities in the Asia Pacific animal vaccines market over the coming years, making it an attractive sector for investors and stakeholders in the animal healthcare industry.
Global sales of companion animal vaccines accounted for revenues over $2.5 billion in 2021.
The statistic stating that global sales of companion animal vaccines generated revenues exceeding $2.5 billion in 2021 highlights the significant economic impact of the companion animal vaccine industry. This figure indicates the substantial demand for preventive healthcare products for pets worldwide. The growth in sales of companion animal vaccines can be attributed to factors such as increasing pet ownership rates, rising awareness about the importance of vaccinations for animal health, and advancements in veterinary medicine. The revenue generated underscores the financial importance of the companion animal healthcare sector and emphasizes the ongoing prioritization of pet health by owners and veterinarians globally.
The global market for animal vaccines was dominated by livestock applications, which accounted for 60.6% in 2021.
The statistic indicates that the majority of the global animal vaccine market in 2021 was attributed to livestock applications, accounting for 60.6%. This suggests that the demand for vaccines in livestock animals such as cattle, poultry, and pigs was significantly higher compared to other types of animals such as pets or wildlife. The dominance of livestock applications in the market could be driven by several factors, including the need to protect animal health and prevent disease outbreaks in large-scale farming operations. This statistic underscores the importance of vaccine development and distribution in the livestock sector to ensure the health and productivity of animals and sustainably meet global food demands.
The live attenuated vaccines segment is projected to reach $7.7 billion by 2028.
The statistic “The live attenuated vaccines segment is projected to reach $7.7 billion by 2028” forecasts the financial growth of a specific subcategory within the vaccine industry. Live attenuated vaccines are a type of vaccine that contains weakened forms of viruses or bacteria to generate an immune response without causing illness. The projected value indicates that there is expected to be a substantial increase in the demand and market value of these vaccines by the year 2028, potentially driven by factors such as public health initiatives, advancements in vaccine development, and increased awareness of the importance of immunization. This projection suggests significant opportunities for growth and investment within the live attenuated vaccines sector in the coming years.
In 2021, bovine vaccines held a 30% share of the livestock vaccines market.
The statistic “In 2021, bovine vaccines held a 30% share of the livestock vaccines market” indicates that out of all the vaccines used in livestock animals during the year 2021, 30% of them were specifically targeted towards bovine animals, such as cattle. This suggests that bovine vaccines were a significant component of the overall market for livestock vaccines, implying a high demand or prevalence of vaccination practices for cattle in the industry. The statistic highlights the importance of bovine health and vaccination in the livestock sector in 2021, underlining the focus on disease prevention and management strategies for this particular species within the broader context of animal health management.
The revenue from porcine vaccines is expected to hit around $2.2 billion by 2027.
The statistic that the revenue from porcine vaccines is expected to reach around $2.2 billion by 2027 indicates a significant projected growth in the market for vaccines designed for pigs. This prediction suggests a rising demand for porcine vaccines over the coming years, likely driven by factors such as increasing concerns about animal health and productivity, as well as a greater emphasis on disease prevention within the livestock industry. The expected substantial revenue figure also reflects the potential profitability of the porcine vaccine market and the investments being made in research, development, and commercialization of these products to meet the growing needs of pig farmers and the broader swine industry.
Zoetis Inc. accounted for the largest share of the animal vaccines market in 2020.
The statistic “Zoetis Inc. accounted for the largest share of the animal vaccines market in 2020” indicates that Zoetis Inc., a leading animal health company, held the highest market share in the animal vaccines industry for the year 2020. This suggests that Zoetis Inc. was the dominant player in terms of revenue or sales within the animal vaccines market, surpassing its competitors. As a key player in the industry, Zoetis Inc.’s market leadership could be attributed to factors such as its extensive product portfolio, strong distribution network, brand reputation, and potentially its research and development capabilities. This statistic highlights Zoetis Inc.’s significant presence and influence in the animal vaccines market during the specified period.
Europe is predicted to grow at a CAGR of more than 5.3% in the animal vaccines market during the forecast period.
This statistic indicates that the animal vaccines market in Europe is projected to experience a Compound Annual Growth Rate (CAGR) of over 5.3% over a specified forecast period. This suggests that there is anticipated growth and expansion within the animal vaccines market in Europe. A higher CAGR implies a stronger rate of growth, indicating potential opportunities for increased demand and revenue in the industry. Factors such as advancements in veterinary medicine, increasing awareness about animal health, and growing emphasis on preventive healthcare for animals may contribute to this positive growth trend.
The vet clinics segment emerged as the largest revenue generator in 2021, with a share of 52.1%.
This statistic indicates that in 2021, the vet clinics segment accounted for the highest proportion of revenue compared to other segments in the industry. Specifically, the vet clinics segment generated 52.1% of the total revenue in the industry, making it the most significant revenue generator among all segments. This suggests that vet clinics were the primary drivers of revenue growth and profitability within the industry during the specified period. Understanding the dominance of the vet clinics segment in revenue generation can provide valuable insights into the dynamics of the industry, market trends, and potentially the preferences or needs of consumers in the pet care sector.
By 2025, the market for aquaculture vaccines is expected to reach $401.4 million.
The statistic “By 2025, the market for aquaculture vaccines is expected to reach $401.4 million” indicates a projected growth in the market size for vaccines specifically designed for aquaculture purposes. Aquaculture, which involves the farming of aquatic organisms such as fish and shellfish, is a rapidly expanding industry due to increasing global demand for seafood. The anticipated market value of $401.4 million by 2025 reflects the increasing awareness among aquaculture producers about the importance of disease prevention and management in their operations. This statistic suggests a growing investment in aquaculture vaccines as a proactive measure to protect farmed aquatic species from diseases, thereby supporting the sustainable growth of the aquaculture industry in the coming years.
The market for swine influenza vaccines is anticipated to grow at a CAGR of more than 7% between 2022 and 2028.
This statistic indicates that the market for swine influenza vaccines is expected to experience a Compound Annual Growth Rate (CAGR) of over 7% during the period from 2022 to 2028. This growth projection suggests a positive trend in the demand for swine influenza vaccines over the specified timeframe. The CAGR is a measure used to represent the average annual growth rate of an investment or market, smoothing out fluctuations to provide a more accurate picture of growth trends. A CAGR of more than 7% indicates a substantial growth rate over the next six years, reflecting potential opportunities for vaccine manufacturers and healthcare providers operating in the swine influenza vaccine market.
References
0. – https://www.www.grandviewresearch.com
1. – https://www.www.mordorintelligence.com
2. – https://www.www.gminsights.com
3. – https://www.www.statista.com
4. – https://www.www.meticulousresearch.com
5. – https://www.www.marketsandmarkets.com
6. – https://www.www.globenewswire.com
7. – https://www.www.databridgemarketresearch.com
8. – https://www.www.visiongain.com
9. – https://www.www.fortunebusinessinsights.com
10. – https://www.www.alliedmarketresearch.com
11. – https://www.www.transparencymarketresearch.com
